Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han: SPRD rats

D. S. Keith, Vicente Torres, C. M. Johnson, K. E. Holley

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

We found that the administration of an angiotensin I-converting enzyme inhibitor and sodium chloride loading lessen the development of renal cystic disease induced by 2-amino-4-5-diphenylthiazole in rats. To determine whether similar effects could be observed in an autosomal dominant model of polycystic kidney disease, heterozygous cystic (Cy/+) and homozygous normal (+/+) Han:SPRD rats were divided into experimental groups at 3 weeks of age. The first study included four groups receiving enalapril (50 mg/L), losartan (400 mg/L), hydralazine (80 mg/L), or no drug in their drinking water. The second study included four groups fed a sodium-deficient diet or the same diet supplemented with 0.25%, 0.6%, or 3.3% sodium chloride. The Cy/+ rats receiving enalapril had lower kidney weights and histologic scores than those in the control group, and lower kidney weights, plasma creatinines, and histologic scores than those in the hydralazine group. The Cy/+ rats receiving losartan had lower plasma creatinines and histologic scores than those in the control and hydralazine treatment groups. A sodium-deficient diet markedly blunted the growth of the animals and the development of cystic disease. Increases in the sodium content of the diet in the other three groups were accompanied by higher relative kidney weights and histology scores, while the levels of plasma creatinine were not significantly different. Regression of the cystic disease was observed between 3 and 4 months of age. These results indicate that the development of autosomal dominant polycystic kidney disease in the rat can be modulated by pharmacologic and nutritional factors. Whereas the administration of an AT1 angiotensin II antagonist or an angiotensin I-converting enzyme inhibitor had a protective effect, increasing the sodium chloride contents of the diet worsened the severity of the renal cystic disease in this animal model.

Original languageEnglish (US)
Pages (from-to)491-498
Number of pages8
JournalAmerican Journal of Kidney Diseases
Volume24
Issue number3
StatePublished - 1994

Fingerprint

Polycystic Kidney Diseases
Enalapril
Losartan
Sodium Chloride
Hydralazine
Diet
Cystic Kidney Diseases
Autosomal Dominant Polycystic Kidney
Creatinine
Sodium
Kidney
Angiotensin-Converting Enzyme Inhibitors
Weights and Measures
Animal Disease Models
Growth and Development
Angiotensin II
Drinking Water
Histology
Control Groups
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nephrology

Cite this

Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han : SPRD rats. / Keith, D. S.; Torres, Vicente; Johnson, C. M.; Holley, K. E.

In: American Journal of Kidney Diseases, Vol. 24, No. 3, 1994, p. 491-498.

Research output: Contribution to journalArticle

@article{fdebe5f30dac417da13c7d640b3d98e9,
title = "Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han: SPRD rats",
abstract = "We found that the administration of an angiotensin I-converting enzyme inhibitor and sodium chloride loading lessen the development of renal cystic disease induced by 2-amino-4-5-diphenylthiazole in rats. To determine whether similar effects could be observed in an autosomal dominant model of polycystic kidney disease, heterozygous cystic (Cy/+) and homozygous normal (+/+) Han:SPRD rats were divided into experimental groups at 3 weeks of age. The first study included four groups receiving enalapril (50 mg/L), losartan (400 mg/L), hydralazine (80 mg/L), or no drug in their drinking water. The second study included four groups fed a sodium-deficient diet or the same diet supplemented with 0.25{\%}, 0.6{\%}, or 3.3{\%} sodium chloride. The Cy/+ rats receiving enalapril had lower kidney weights and histologic scores than those in the control group, and lower kidney weights, plasma creatinines, and histologic scores than those in the hydralazine group. The Cy/+ rats receiving losartan had lower plasma creatinines and histologic scores than those in the control and hydralazine treatment groups. A sodium-deficient diet markedly blunted the growth of the animals and the development of cystic disease. Increases in the sodium content of the diet in the other three groups were accompanied by higher relative kidney weights and histology scores, while the levels of plasma creatinine were not significantly different. Regression of the cystic disease was observed between 3 and 4 months of age. These results indicate that the development of autosomal dominant polycystic kidney disease in the rat can be modulated by pharmacologic and nutritional factors. Whereas the administration of an AT1 angiotensin II antagonist or an angiotensin I-converting enzyme inhibitor had a protective effect, increasing the sodium chloride contents of the diet worsened the severity of the renal cystic disease in this animal model.",
author = "Keith, {D. S.} and Vicente Torres and Johnson, {C. M.} and Holley, {K. E.}",
year = "1994",
language = "English (US)",
volume = "24",
pages = "491--498",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han

T2 - SPRD rats

AU - Keith, D. S.

AU - Torres, Vicente

AU - Johnson, C. M.

AU - Holley, K. E.

PY - 1994

Y1 - 1994

N2 - We found that the administration of an angiotensin I-converting enzyme inhibitor and sodium chloride loading lessen the development of renal cystic disease induced by 2-amino-4-5-diphenylthiazole in rats. To determine whether similar effects could be observed in an autosomal dominant model of polycystic kidney disease, heterozygous cystic (Cy/+) and homozygous normal (+/+) Han:SPRD rats were divided into experimental groups at 3 weeks of age. The first study included four groups receiving enalapril (50 mg/L), losartan (400 mg/L), hydralazine (80 mg/L), or no drug in their drinking water. The second study included four groups fed a sodium-deficient diet or the same diet supplemented with 0.25%, 0.6%, or 3.3% sodium chloride. The Cy/+ rats receiving enalapril had lower kidney weights and histologic scores than those in the control group, and lower kidney weights, plasma creatinines, and histologic scores than those in the hydralazine group. The Cy/+ rats receiving losartan had lower plasma creatinines and histologic scores than those in the control and hydralazine treatment groups. A sodium-deficient diet markedly blunted the growth of the animals and the development of cystic disease. Increases in the sodium content of the diet in the other three groups were accompanied by higher relative kidney weights and histology scores, while the levels of plasma creatinine were not significantly different. Regression of the cystic disease was observed between 3 and 4 months of age. These results indicate that the development of autosomal dominant polycystic kidney disease in the rat can be modulated by pharmacologic and nutritional factors. Whereas the administration of an AT1 angiotensin II antagonist or an angiotensin I-converting enzyme inhibitor had a protective effect, increasing the sodium chloride contents of the diet worsened the severity of the renal cystic disease in this animal model.

AB - We found that the administration of an angiotensin I-converting enzyme inhibitor and sodium chloride loading lessen the development of renal cystic disease induced by 2-amino-4-5-diphenylthiazole in rats. To determine whether similar effects could be observed in an autosomal dominant model of polycystic kidney disease, heterozygous cystic (Cy/+) and homozygous normal (+/+) Han:SPRD rats were divided into experimental groups at 3 weeks of age. The first study included four groups receiving enalapril (50 mg/L), losartan (400 mg/L), hydralazine (80 mg/L), or no drug in their drinking water. The second study included four groups fed a sodium-deficient diet or the same diet supplemented with 0.25%, 0.6%, or 3.3% sodium chloride. The Cy/+ rats receiving enalapril had lower kidney weights and histologic scores than those in the control group, and lower kidney weights, plasma creatinines, and histologic scores than those in the hydralazine group. The Cy/+ rats receiving losartan had lower plasma creatinines and histologic scores than those in the control and hydralazine treatment groups. A sodium-deficient diet markedly blunted the growth of the animals and the development of cystic disease. Increases in the sodium content of the diet in the other three groups were accompanied by higher relative kidney weights and histology scores, while the levels of plasma creatinine were not significantly different. Regression of the cystic disease was observed between 3 and 4 months of age. These results indicate that the development of autosomal dominant polycystic kidney disease in the rat can be modulated by pharmacologic and nutritional factors. Whereas the administration of an AT1 angiotensin II antagonist or an angiotensin I-converting enzyme inhibitor had a protective effect, increasing the sodium chloride contents of the diet worsened the severity of the renal cystic disease in this animal model.

UR - http://www.scopus.com/inward/record.url?scp=0027935786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027935786&partnerID=8YFLogxK

M3 - Article

C2 - 8079975

AN - SCOPUS:0027935786

VL - 24

SP - 491

EP - 498

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 3

ER -